Anew Labs, a former unit of ByteDance, has secured US$290 million in funding at a US$1.5 billion valuation. The Shanghai-based AI drug discovery firm's funding round was backed by prominent venture capital firms including HSG (formerly Sequoia China), IDG Capital, and 5Y Capital. Anew Labs utilizes AI models for biomolecular structure prediction and design, including its own AnewFold model and an open-source version of Google DeepMind's AlphaFold 3. AI
IMPACT Accelerates AI's role in drug design and signals strong investor confidence in AI-driven pharmaceutical innovation.
RANK_REASON Significant funding round for an AI drug discovery startup. [lever_c_demoted from significant: ic=1 ai=0.7]
- 5Y Capital
- AlphaFold 3
- AnewFold
- Anew Labs
- Anthropic
- ByteDance
- Google DeepMind
- IDG Capital
- Isomorphic Labs
- Protenix
AI-generated summary · Google Gemini · from 1 sources. How we write summaries →